Cargando…
The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449681/ https://www.ncbi.nlm.nih.gov/pubmed/26237380 http://dx.doi.org/10.3390/jcm3020373 |
_version_ | 1782373899171790848 |
---|---|
author | Alvarez Palomo, Ana Belen Lucas, Michaela Dilley, Rodney J. McLenachan, Samuel Chen, Fred Kuanfu Requena, Jordi Sal, Marti Farrera Lucas, Andrew Alvarez, Inaki Jaraquemada, Dolores Edel, Michael J. |
author_facet | Alvarez Palomo, Ana Belen Lucas, Michaela Dilley, Rodney J. McLenachan, Samuel Chen, Fred Kuanfu Requena, Jordi Sal, Marti Farrera Lucas, Andrew Alvarez, Inaki Jaraquemada, Dolores Edel, Michael J. |
author_sort | Alvarez Palomo, Ana Belen |
collection | PubMed |
description | Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues. |
format | Online Article Text |
id | pubmed-4449681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44496812015-07-28 The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation Alvarez Palomo, Ana Belen Lucas, Michaela Dilley, Rodney J. McLenachan, Samuel Chen, Fred Kuanfu Requena, Jordi Sal, Marti Farrera Lucas, Andrew Alvarez, Inaki Jaraquemada, Dolores Edel, Michael J. J Clin Med Review Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues. MDPI 2014-04-04 /pmc/articles/PMC4449681/ /pubmed/26237380 http://dx.doi.org/10.3390/jcm3020373 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Alvarez Palomo, Ana Belen Lucas, Michaela Dilley, Rodney J. McLenachan, Samuel Chen, Fred Kuanfu Requena, Jordi Sal, Marti Farrera Lucas, Andrew Alvarez, Inaki Jaraquemada, Dolores Edel, Michael J. The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation |
title | The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation |
title_full | The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation |
title_fullStr | The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation |
title_full_unstemmed | The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation |
title_short | The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation |
title_sort | power and the promise of cell reprogramming: personalized autologous body organ and cell transplantation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449681/ https://www.ncbi.nlm.nih.gov/pubmed/26237380 http://dx.doi.org/10.3390/jcm3020373 |
work_keys_str_mv | AT alvarezpalomoanabelen thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT lucasmichaela thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT dilleyrodneyj thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT mclenachansamuel thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT chenfredkuanfu thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT requenajordi thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT salmartifarrera thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT lucasandrew thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT alvarezinaki thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT jaraquemadadolores thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT edelmichaelj thepowerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT alvarezpalomoanabelen powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT lucasmichaela powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT dilleyrodneyj powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT mclenachansamuel powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT chenfredkuanfu powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT requenajordi powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT salmartifarrera powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT lucasandrew powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT alvarezinaki powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT jaraquemadadolores powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation AT edelmichaelj powerandthepromiseofcellreprogrammingpersonalizedautologousbodyorganandcelltransplantation |